This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
|Articles|January 17, 2008
Dockets Comments No Longer Accepted Through FDA Website
Author(s)Pharmaceutical Technology Editors
The US Food and Drug Administration?s website will no longer allow the public to electronically submit comments to its dockets.
Advertisement
Rockville, MD (Jan. 11)-The US Food and Drug Administration’s website (
As part of the federal eRulemaking Initiative, FDMS is “designed so that the public has a single point of access to the public dockets across the Federal government” (Federal Register Notice, Jan. 14, 2008). The system is accessible at
Any docket created after Jan. 15, 2008, will receive a docket ID, established by the FDMS system. Those dockets created on or before Jan. 15, 2008, also will receive a docket ID established by FDMS and will include a reference to its original docket identification number previously assigned by FDA (legacy numbers).
The complete announcement regarding FDMS can be found
Advertisement
Related to this article
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Advertisement
Advertisement